Details checkedStatus needs checkingCheckedcompany

GJB2 hearing loss gene therapy by Eli Lilly

Also known as: GJB2 program, Connexin 26 program

Eli Lilly and Company

Primary source

Company

Eli Lilly and Company

Program Type

Therapeutic

Modality

Gene Therapy

Stage

Preclinical

Status

Unknown

Target Gene

GJB2

Route / Mode

Unknown

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

genetic, pediatric, congenital, pre-lingual

Trial IDs

Mechanism

AAV-based inner-ear gene therapy intended to restore GJB2 expression in supporting cells for connexin 26-related hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Genetic Hearing Loss

Notes

Verified as a real Akouos-originated GJB2 gene therapy program acquired by Lilly. Lilly's current public clinical pipeline page is dated April 30, 2026 and does not disclose this preclinical asset or a program-specific development status; HearScape therefore verifies existence and ownership while keeping public current status as Unknown.

Evidence & Sources

3 structured sources

company

Supports: canonicalName, company, allCompanies, modality, targetGene, indications, stage, notes

IDs: GJB2

Open

company

Supports: modality, mechanism, targetGene, indications, stage, populationTags

IDs: GJB2

Open

company

Supports: notes, status